Onco-Innovations Turns to Insider and Shareholder Loans for C$280,000 Cash Infusion

Onco-Innovations raises C$280K in high-interest insider and shareholder loans to fund cancer research as shares fall 67%.

The cancer research company Onco-Innovations has tapped internal resources to shore up its liquidity, securing C$280,000 in new loans as its stock continues to slide and clinical work on its nanoparticle-based drug ONC010 intensifies. The financing package, drawn from both the chief medical officer and outside shareholders, provides enough runway to keep contracted research moving forward but adds fresh repayment obligations that will test management’s ability to deliver milestones.

The largest chunk comes directly from Dr. Islam Mohamed, the company’s medical chief, who is lending C$200,000. These funds are ring-fenced for payments to external research and development service providers, with interest accruing at 1% per month — an effective annual rate of roughly 12.7%. The principal and interest must be returned in two equal installments due on September 13 and November 13, 2026. If Onco-Innovations defaults, a penalty rate of 3% per month kicks in, underlining the lender’s willingness to enforce terms. Because the loan involves a board member, it qualifies for certain regulatory exemptions that streamline its approval.

A separate group of two non-management shareholders has contributed the remaining C$80,000 at a much steeper cost: 15% annual interest. This money is earmarked for general corporate expenses, and the lenders retain the right to demand full repayment at any time — a feature that introduces an element of balance-sheet unpredictability. The higher rate reflects the subordinate risk these investors are taking relative to company insiders.

The fresh capital arrives at a moment when market sentiment remains sour. Onco-Innovations’ shares recently traded at €0.3755, down roughly 9% in the most recent session and 56% since the start of the year. Over the trailing twelve months, the equity has lost about 67% of its value, reflecting a prolonged erosion of confidence as the pre-revenue biotech burns through cash without a near-term catalyst. The new loans are purely debt, not convertible, so they will not dilute existing shareholders, but they also do nothing to address the structural funding gap beyond the short term.

With the first repayment tranche to Dr. Mohamed falling due in September 2026, the company has a little over 18 months to either generate revenue from its oncology pipeline or secure more substantial financing. For now, the C$280,000 ensures that external research partners continue their work on ONC010, but the clock is ticking on both the development program and the company’s ability to stay ahead of its liabilities.